Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 410

1.

Alterations in Wnt- and/or STAT3 signaling pathways and the immune microenvironment during metastatic progression.

Kim SJ, Garcia-Recio S, Creighton CJ, Perou CM, Rosen JM.

Oncogene. 2019 Jul 9. doi: 10.1038/s41388-019-0852-0. [Epub ahead of print]

PMID:
31289359
2.

The MMTV-Wnt1 murine model produces two phenotypically distinct subtypes of mammary tumors with unique therapeutic responses to an EGFR inhibitor.

Pfefferle AD, Darr DB, Calhoun BC, Mott KR, Rosen JM, Perou CM.

Dis Model Mech. 2019 Jul 5;12(7). pii: dmm037192. doi: 10.1242/dmm.037192.

3.

Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series.

Picornell AC, Echavarria I, Alvarez E, López-Tarruella S, Jerez Y, Hoadley K, Parker JS, Del Monte-Millán M, Ramos-Medina R, Gayarre J, Ocaña I, Cebollero M, Massarrah T, Moreno F, García Saenz JA, Gómez Moreno H, Ballesteros A, Ruiz Borrego M, Perou CM, Martin M.

BMC Genomics. 2019 Jun 3;20(1):452. doi: 10.1186/s12864-019-5849-0.

4.

The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy.

Waks AG, Stover DG, Guerriero JL, Dillon D, Barry WT, Gjini E, Hartl C, Lo W, Savoie J, Brock J, Wesolowski R, Li Z, Damicis A, Philips AV, Wu Y, Yang F, Sullivan A, Danaher P, Brauer HA, Osmani W, Lipschitz M, Hoadley KA, Goldberg M, Perou CM, Rodig S, Winer EP, Krop IE, Mittendorf EA, Tolaney SM.

Clin Cancer Res. 2019 May 6. doi: 10.1158/1078-0432.CCR-19-0173. [Epub ahead of print]

PMID:
31061067
5.

MERTK mediated novel site Akt phosphorylation alleviates SAV1 suppression.

Jiang Y, Zhang Y, Leung JY, Fan C, Popov KI, Su S, Qian J, Wang X, Holtzhausen A, Ubil E, Xiang Y, Davis I, Dokholyan NV, Wu G, Perou CM, Kim WY, Earp HS, Liu P.

Nat Commun. 2019 Apr 3;10(1):1515. doi: 10.1038/s41467-019-09233-7.

6.

I-Boost: an integrative boosting approach for predicting survival time with multiple genomics platforms.

Wong KY, Fan C, Tanioka M, Parker JS, Nobel AB, Zeng D, Lin DY, Perou CM.

Genome Biol. 2019 Mar 7;20(1):52. doi: 10.1186/s13059-019-1640-4.

7.

Separation of breast cancer and organ microenvironment transcriptomes in metastases.

Alzubi MA, Turner TH, Olex AL, Sohal SS, Tobin NP, Recio SG, Bergh J, Hatschek T, Parker JS, Sartorius CA, Perou CM, Dozmorov MG, Harrell JC.

Breast Cancer Res. 2019 Mar 6;21(1):36. doi: 10.1186/s13058-019-1123-2.

8.

The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours.

Lundberg A, Lindström LS, Li J, Harrell JC, Darai-Ramqvist E, Sifakis EG, Foukakis T, Perou CM, Czene K, Bergh J, Tobin NP.

Breast Cancer Res. 2019 Feb 28;21(1):34. doi: 10.1186/s13058-019-1121-4.

9.

Improved Indel Detection in DNA and RNA via Realignment with ABRA2.

Mose LE, Perou CM, Parker JS.

Bioinformatics. 2019 Jan 15. doi: 10.1093/bioinformatics/btz033. [Epub ahead of print]

PMID:
30649250
10.

Differences in race, molecular and tumor characteristics among women diagnosed with invasive ductal and lobular breast carcinomas.

Williams LA, Hoadley KA, Nichols HB, Geradts J, Perou CM, Love MI, Olshan AF, Troester MA.

Cancer Causes Control. 2019 Jan;30(1):31-39. doi: 10.1007/s10552-018-1121-1. Epub 2019 Jan 8.

11.

DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer.

Matsunuma R, Chan DW, Kim BJ, Singh P, Han A, Saltzman AB, Cheng C, Lei JT, Wang J, Roberto da Silva L, Sahin E, Leng M, Fan C, Perou CM, Malovannaya A, Ellis MJ.

Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):E11978-E11987. doi: 10.1073/pnas.1810598115. Epub 2018 Nov 29.

12.

Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer.

Tanioka M, Mott KR, Hollern DP, Fan C, Darr DB, Perou CM.

Genome Med. 2018 Nov 30;10(1):86. doi: 10.1186/s13073-018-0597-3.

13.

A mouse model featuring tissue-specific deletion of p53 and Brca1 gives rise to mammary tumors with genomic and transcriptomic similarities to human basal-like breast cancer.

Hollern DP, Contreras CM, Dance-Barnes S, Silva GO, Pfefferle AD, Xiong J, Darr DB, Usary J, Mott KR, Perou CM.

Breast Cancer Res Treat. 2019 Feb;174(1):143-155. doi: 10.1007/s10549-018-5061-y. Epub 2018 Nov 27.

14.

Tumor mutational burden is a determinant of immune-mediated survival in breast cancer.

Thomas A, Routh ED, Pullikuth A, Jin G, Su J, Chou JW, Hoadley KA, Print C, Knowlton N, Black MA, Demaria S, Wang E, Bedognetti D, Jones WD, Mehta GA, Gatza ML, Perou CM, Page DB, Triozzi P, Miller LD.

Oncoimmunology. 2018 Jul 30;7(10):e1490854. doi: 10.1080/2162402X.2018.1490854. eCollection 2018.

15.

Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer.

Wang Y, Xu X, Maglic D, Dill MT, Mojumdar K, Ng PK, Jeong KJ, Tsang YH, Moreno D, Bhavana VH, Peng X, Ge Z, Chen H, Li J, Chen Z, Zhang H, Han L, Du D, Creighton CJ, Mills GB; Cancer Genome Atlas Research Network, Camargo F, Liang H.

Cell Rep. 2018 Oct 30;25(5):1304-1317.e5. doi: 10.1016/j.celrep.2018.10.001.

16.

Cdh1 and Pik3ca Mutations Cooperate to Induce Immune-Related Invasive Lobular Carcinoma of the Breast.

An Y, Adams JR, Hollern DP, Zhao A, Chang SG, Gams MS, Chung PED, He X, Jangra R, Shah JS, Yang J, Beck LA, Raghuram N, Kozma KJ, Loch AJ, Wang W, Fan C, Done SJ, Zacksenhaus E, Guidos CJ, Perou CM, Egan SE.

Cell Rep. 2018 Oct 16;25(3):702-714.e6. doi: 10.1016/j.celrep.2018.09.056.

17.

Integrative Molecular Characterization of Malignant Pleural Mesothelioma.

Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, Tarpey P, Danilova L, Drill E, Gibb EA, Bowlby R, Kanchi R, Osmanbeyoglu HU, Sekido Y, Takeshita J, Newton Y, Graim K, Gupta M, Gay CM, Diao L, Gibbs DL, Thorsson V, Iype L, Kantheti H, Severson DT, Ravegnini G, Desmeules P, Jungbluth AA, Travis WD, Dacic S, Chirieac LR, Galateau-Sallé F, Fujimoto J, Husain AN, Silveira HC, Rusch VW, Rintoul RC, Pass H, Kindler H, Zauderer MG, Kwiatkowski DJ, Bueno R, Tsao AS, Creaney J, Lichtenberg T, Leraas K, Bowen J; TCGA Research Network, Felau I, Zenklusen JC, Akbani R, Cherniack AD, Byers LA, Noble MS, Fletcher JA, Robertson AG, Shen R, Aburatani H, Robinson BW, Campbell P, Ladanyi M.

Cancer Discov. 2018 Dec;8(12):1548-1565. doi: 10.1158/2159-8290.CD-18-0804. Epub 2018 Oct 15.

PMID:
30322867
18.

Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis.

Shu X, Wu L, Khankari NK, Shu XO, Wang TJ, Michailidou K, Bolla MK, Wang Q, Dennis J, Milne RL, Schmidt MK, Pharoah PDP, Andrulis IL, Hunter DJ, Simard J, Easton DF, Zheng W; Breast Cancer Association Consortium .

Int J Epidemiol. 2018 Oct 1. doi: 10.1093/ije/dyy201. [Epub ahead of print]

PMID:
30277539
19.

A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily.

Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A, Li X, Lorenzi PL, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Ravikumar V, Manyam G, Rao A, Shelley S, Liu Y, Ju Z, Hansel D, de Velasco G, Pennathur A, Andersen JB, O'Rourke CJ, Ohshiro K, Jogunoori W, Nguyen BN, Li S, Osmanbeyoglu HU, Ajani JA, Mani SA, Houseman A, Wiznerowicz M, Chen J, Gu S, Ma W, Zhang J, Tong P, Cherniack AD, Deng C, Resar L; Cancer Genome Atlas Research Network, Weinstein JN, Mishra L, Akbani R.

Cell Syst. 2018 Oct 24;7(4):422-437.e7. doi: 10.1016/j.cels.2018.08.010. Epub 2018 Sep 26.

20.

Image analysis with deep learning to predict breast cancer grade, ER status, histologic subtype, and intrinsic subtype.

Couture HD, Williams LA, Geradts J, Nyante SJ, Butler EN, Marron JS, Perou CM, Troester MA, Niethammer M.

NPJ Breast Cancer. 2018 Sep 3;4:30. doi: 10.1038/s41523-018-0079-1. eCollection 2018.

Supplemental Content

Loading ...
Support Center